Obese Schizophrenia Spectrum Patients Have Significantly Higher 10-Year General Cardiovascular Risk and Vascular Ages than Obese Individuals without Severe Mental Illness

Psychosomatics

Volumn 54, Issue 1, 2013, Pages 67-73

  Ratliff, Joseph C ^a   Palmese, Laura B ^a   Reutenauer, Erin L ^a   Srihari, Vinod H ^a   Tek, Cenk ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BUSPIRONE; CITALOPRAM; CLONAZEPAM; CLOZAPINE; DIAZEPAM; FLUPHENAZINE; GABAPENTIN; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMIPRAMINE; LAMOTRIGINE; LITHIUM; LORAZEPAM; MIRTAZAPINE; OLANZAPINE; PALIPERIDONE; PAROXETINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TIOTIXENE; TRAZODONE; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESE SCHIZOPHRENIA SPECTRUM; OBESITY; SCHIZOPHRENIA; SMOKING; SYSTOLIC BLOOD PRESSURE;

ADULT; AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFE EXPECTANCY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PSYCHOTIC DISORDERS; RISK ASSESSMENT; RISK FACTORS; SCHIZOPHRENIA; SEX FACTORS; SMOKING;

EID: 84875803407     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2012.03.001     Document Type: Article

References (40)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., Adams R.J., Berry J.D., Brown T.M., et al. Heart disease and stroke statistics-2011 update. Circulation 2011, 123(4):e18-e209.
2. Jackson R., Lawes C.M.M., Bennett D.A., Milne R.J., Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005, 365(9457):434-441.
3. Cleeman J.I. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285(19):2486-2497.
4. Ridker P.M., Buring J.E., Rifai N., Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women. JAMA 2007, 297(6):611-619.
5. Hippisley-Cox J., Coupland C., Vinogradova Y., Robson J., May M., Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007, 335(7611):136.
6. D'Agostino R.B., Vasan R.S., Pencina M.J., Wolf P.A., Cobain M., Massaro J.M., et al. General cardiovascular risk profile for use in primary care. Circulation 2008, 117(6):743-753.
7. Hennekens C.H., Hennekens A.R., Hollar D., Casey D.E. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005, 150(6):1115-1121.
8. Chang C.-K., Hayes R.D., Perera G., Broadbent M.T.M., Fernandes A.C., Lee W.E., et al. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS ONE 2011, 6(5):e19590.
9. Holt R.I.G., Peveler R.C. Obesity, serious mental illness, and antipsychotic drugs. Diabetes Obesity Metab 2009, 11(7):665-679.
10. Sukdeb M. High prevalence of type II diabetes in schizophrenic patients. Schizophr Res 1995, 15(1/2):195.
11. Wilson P.W.F., D'Agostino R.B., Sullivan L., Parise H., Kannel W.B. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002, 162(16):1867-1872.
12. Peeters A., Barendregt J.J., Willekens F., Mackenbach J.P., Mamun A.A., Bonneux L., et al. Obesity in adulthood and its consequences for life expectancy: A Life- analysis. Ann Intern Med 2003, 138(1):24-32.
13. Brown S., Birtwistle J., Roe L., Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999, 29(3):697-701.
14. Vancampfort D., De Hert M., Skjerven L.H., Gyllensten A.L., Parker A., Mulders N., et al. International Organization of Physical Therapy in Mental Health consensus on physical activity within multidisciplinary rehabilitation programs for minimizing cardio-metabolic risk in patients with schizophrenia. Disabil Rehabil 2012, 34(1):1-12.
15. Simon V., Van Winkel R., De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent?. A literature review. J Clin Psychiatry 2009, 70(7):1041-1050.
16. Chaggar P.S., Shaw S.M., Williams S.G. Effect of antipsychotic medications on glucose and lipid levels. J Clin Pharmacol 2011, 51(5):631-638.
17. Meyer J.M., Stahl S.M. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009, 119(1):4-114.
18. De Hert M., Detraux J., van Winkel R., Yu W., Correll C.U. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Endocrinol Rev 2011, 8(2):114-126.
19. Nasrallah H.A., Meyer J.M., Goff D.C., McEvoy J.P., Davis S.M., Stroup T.S., et al. Low rates of treatment for hypertension, dyslipidemia, and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006, 86(1/3):15-22.
20. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV-TR Axis I disorders, Patient Edition. (SCID-I/P) 2007, Biometrics Research, New York State Psychiatric Institute, New York, revision.
21. Alberti K.G.M.M., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645.
22. Gardner D.M., Murphy A.L., O'Donnell H., Centorrino F., Baldessarini R.J. International consensus study of antipsychotic dosing. Am J Psychiatry 2010, 167(6):686-693.
23. Bobes J., Arango C., Aranda P., Carmena R., Garcia-Garcia M., Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study. Schizophr Res 2007, 90(1/3):162-173.
24. Goff D.C., Sullivan L.M., McEvoy J.P., Meyer J.M., Nasrallah H.A., Daumit G.L., et al. A comparison of 10-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005, 80(1):45-53.
25. Cohn T., Prud'homme D., Streiner D., Kameh H., Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: High prevalence of the metabolic syndrome. Can J Psychiatry 2004, 49(11):753-760.
26. Phutane V.H., Tek C., Chwastiak L., Ratliff J.C., Ozyuksel B., Woods S.W., et al. Cardiovascular risk in a first-episode psychosis sample: A "critical period" for prevention?. Schizophr Res 2011, 127(1/3):257-261.
27. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80(1):19-32.
28. Wormser D., Kaptoge S., Di Angelantonio E., Wood A.M., Pennells L., Thompson A., et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 2011, 377(9771):1085-1095.
29. Schorr S.G., Slooff C.J., Bruggeman R., Taxis K. The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. J Psychiatr Res 2009, 43(13):1106-1111.
30. Wildgust H.J., Beary M. Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?. J Psychopharmacol (Oxford, Eng) 2010, 24(4 Suppl):37-50.
31. Willi C., Bodenmann P., Ghali W.A., Faris P.D., Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007, 298(22):2654-2664.
32. Gruer L., Hart C.L., Gordon D.S., Watt G.C.M. Effect of tobacco smoking on survival of men and women by social position: A 28-year cohort study. BMJ 2009, 338:b480.
33. Lieberman J.A., Scott Stroup T., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353(12):1209-1223.
34. Chapman M.J., Ginsberg H.N., Amarenco P., Andreotti F., Borén J., Catapano A.L., et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011, 32(11):1345-1361.
35. Wu M.-K., Wang C.-K., Bai Y.-M., Huang C.-Y., Lee S.-D. Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a 6-month diet and physical activity program. Psychiatr Serv 2007, 58(4):544-550.
36. Kwon J.S., Choi J.-S., Bahk W.-M., Kim C.Y., Kim C.H., Shin Y.C., et al. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial. J Clin Psychiatry 2006, 67(4):547-553.
37. De Hert M., Schreurs V., Vancampfort D., Van Winkel R. Metabolic syndrome in people with schizophrenia: A review. World Psychiatry 2009, 8(1):15-22.
38. Wilson P.W.F., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97(18):1837-1847.
39. Osborn D.P.J., Nazareth I., King M.B. Physical activity, dietary habits, and coronary heart disease risk factor knowledge amongst people with severe mental illness. Soc Psychiatry Psychiatr Epidemiol 2007, 42(10):787-793.
40. Tek C., Ratliff J.C., Chwastiak L. Pharmacological treatment of obesity. Psychiatr Ann 2011, 41(10):489-495.